期刊文献+

紫杉醇注射液不良反应的预防及处理 被引量:8

Prevention and treatment analysis of adverse effects on paclitaxel injection
原文传递
导出
摘要 目的紫杉醇注射液不良反应的预防及处理。方法回顾性分析医院2012年6月-2015年6月采用紫杉醇注射液治疗恶性肿瘤患者80例的临床资料,将剂量为紫杉醇注射液135~175 mg/m2加入浓度为0.9%氯化钠溶液中配制成500 ml的溶液,采用特制材料的输液瓶及输液器进行静脉滴注。观察不良反应发生情况。结果 80例恶性肿瘤患者中,出现不良反应23例(28.75%)。不良反应主要包括骨髓抑制10例,消化道反应8例,肌肉疼痛2例,过敏反应2例及神经毒性1例。结论使用紫杉醇药物时应规范用药标准,严密监测患者生命体征,避免患者出现严重的不良反应。 Objective To analysis the prevention and treatment of adverse effects on paclitaxel injection. Methods Retrospectively analyzed the clinical date of 80 cases patients with malignant neoplasms,treated by paclitaxel injection,from June 2012 to June 2015. Mix paclitaxel injection 135 ~ 175 mg / m2 and 0. 9% sodium chloride solution into 500 ml solution.Used a special material infusion bottle and infusion device for intravenous infusion. Results In 80 cases patients with malignant neoplasms,23 cases patients( 28. 75%) with adverse reactions. Adverse reactions included 10 cases of bone marrow suppression,8 cases of digestive tract reaction,2 cases of muscle pain,2 cases of allergic reaction,1 case of neurotoxicity. Conclusion When using paclitaxel drugs should be standard drug use standards. Vital signs is closely monitored to avoid serious adverse reactions.
作者 张清 ZHANG Qing(Department of Pharmacy, The People's Hospital of Lianshui County, Jiangsu Province, Lianshui 223400, Chin)
出处 《临床合理用药杂志》 2017年第1期5-6,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 紫杉醇注射液 不良反应 预防 Paclitaxel injection Adverse reactions Prevention
  • 相关文献

参考文献7

二级参考文献76

  • 1周卫,翁帼英,陈文忠,庄翌,傅晓阳,程光.紫杉醇脂质体在大鼠体内的组织分布[J].中国药学杂志,2005,40(18):1402-1404. 被引量:54
  • 2Howlader N,Noone AM,Krapcho M,et al.SEER Cancer Statistics Review,1975-2011[M].Bethesda,MD:National Cancer Institute,2011.
  • 3AJCC Cancer Staging Manual[M].6th ed.New York:Spring-Verlag,2002.
  • 4Strauss GM,Herndon JEⅡ,Madus MA,et al.Adjuvant paclitaxel plus carboplatin compared with obsmvation in stage ⅠB nonsmall-cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B,Radiation Therapy Oncology Group,and Nmth Central Cancer Treatment Group Study Groups[J].J Clin Oncol,2008,26(31):5043-5051.
  • 5Strauss GM,Herndon JE Ⅱ,Mad&us MA,et al.Adjuvant chemotherapy in stage ⅠB non-small cell lung cancer (NSCLC):Update of Cancer and Leukemia Group B (CALGB) protocol 9633[J].J Clin Oncol,2006,24(Suppl 18):365s.
  • 6Sandler A,Gray R,Pmr y MC,et al.Paclitaxel-carboplatinalone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355(24):2542-2550.
  • 7KuehlP,Zhang J,Lin Y. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J].Nature Genetics,2001,(04):383-391.doi:10.1038/86882.
  • 8孙燕;石远凯.临床肿瘤内科手册[M]北京:人民卫生出版社,2007142-624.
  • 9Tsai S M,Lin C Y,Wu S H. Side effects after docetaxel treatment in Taiwan Residents breast cancer patients with CYP3A4,CYP3A5,and ABCB1 gene polymorphisms[J].Clinica Chimica Acta,2009,(02):160-165.doi:10.1016/j.cca.2009.03.038.
  • 10Henningsson A,Marsh S,Loos W J. Association of CYP2C8,CYP3A4,CYP3A5,and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel[J].Clinical Cancer Research,2005,(22):8097-8104.

共引文献84

同被引文献75

引证文献8

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部